- Home
- XERS vs EYE Comparison
XERS vs EYE Comparison
Compare XERS & EYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | EYE |
|---|---|---|
| Founded | 2005 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XERS | EYE |
|---|---|---|
| Price | $7.67 | $16.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $10.83 | ★ $31.22 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.00 | ★ 202.78 |
| EPS | N/A | ★ 0.54 |
| Revenue | $49,590,000.00 | ★ $1,987,488,000.00 |
| Revenue This Year | $34.37 | $5.56 |
| Revenue Next Year | $22.86 | $6.58 |
| P/E Ratio | ★ N/A | $29.43 |
| Revenue Growth | ★ 142.67 | 9.00 |
| 52 Week Low | $5.25 | $14.75 |
| 52 Week High | $10.08 | $30.02 |
Technical Indicators
Market Signals| Indicator | XERS | EYE |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 29.46 |
| Support Level | $7.06 | $14.84 |
| Resistance Level | $8.95 | $29.60 |
| Average True Range (ATR) | 0.33 | 0.79 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 6.04 | 2.50 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About EYE National Vision Holdings Inc.
National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.